" /> Von hippel-lindau syndrome - CISMeF





Preferred Label : Von hippel-lindau syndrome;

Symbol : VHLS;

CISMeF acronym : VHL; VHLS;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : VHL;

Included titles and symbols : Von hippel-lindau syndrome, modifiers of;

Description : Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign neoplasms, most frequently retinal, cerebellar, and spinal hemangioblastoma, renal cell carcinoma (RCC), pheochromocytoma, and pancreatic tumors. Neumann and Wiestler (1991) classified VHL as type 1 (without pheochromocytoma) and type 2 (with pheochromocytoma). Brauch et al. (1995) further subdivided VHL type 2 into type 2A (with pheochromocytoma) and type 2B (with pheochromocytoma and renal cell carcinoma). Hoffman et al. (2001) noted that VHL type 2C refers to patients with isolated pheochromocytoma without hemangioblastoma or renal cell carcinoma. McNeill et al. (2009) proposed that patients with VHL syndrome caused by large VHL deletions that include the HSPC300 gene (C3ORF10; 611183) have a specific subtype of VHL syndrome characterized by protection from renal cell carcinoma, which the authors proposed be named VHL type 1B. Nordstrom-O'Brien et al. (2010) provided a review of the genetics of von Hippel-Lindau disease.;

Inheritance : Autosomal dominant;

Molecular basis : Caused by mutation in the von Hippel-Lindau gene (VHL, 608537.0001);

Neoplasia : Pheochromocytoma; Hemangioblastoma, sporadic cerebellar (e.g., 193300.0007); Hypernephroma; Pancreatic cancer; Paraganglioma; Adenocarcinoma of ampulla of Vater;

Prefixed ID : #193300;

Details


You can consult :


Nous contacter.
04/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.